Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-24 @ 11:19 PM
Ignite Modification Date:
2025-12-24 @ 11:19 PM
NCT ID:
NCT00433056
Eligibility Criteria:
Inclusion Criteria:
* Age \> 17 years
* Informed consent signed
* Effective ongoing treatment (HIV-RNA \< 50 copies/ml). Treatment must be based on any triple drug therapy. Patients must be on the same steady therapy for at least 3 months.
* Current CD4 cell count above 600 cells/mcL and nadir of CD4 cell count \> 200 cells/mcL
Exclusion Criteria:
* Childbearing or breastfeeding. Women of childbearing potential will be asked to adopt effective contraceptive methods or behaviors
* Any ongoing grade 4 (WHO) AE or laboratory abnormality with the exclusion of cholesterol, triglycerides for which a grade 3 (AHA) level will be considered an exclusion criteria.
* Previous diagnosis of AIDS
* Patients with HBV coinfection on active anti-HIV treatment with either lamivudine and/or tenofovir
Healthy Volunteers:
False
Sex:
ALL
Minimum Age:
18 Years
Study:
NCT00433056
Study Brief:
Protocol Section:
NCT00433056